Physician profile
Frederick Sk Ling
NPI 1508808304
$48,955.20
in general payments reported to CMS, 2019-2025
8 companies · $6,045 in 2025
The $6,045 reported for 2025 was more than what 85% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,590 · 2020: $6,023 · 2021: $11K · 2022: $9,646 · 2023: $4,661 · 2024: $10K · 2025: $6,045.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $14K · Travel and Lodging: $6,291 · Food and Beverage: $1,160.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $13,550.00 |
| Travel and Lodging | $6,290.70 |
| Food and Beverage | $1,160.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $42,185.09 | 2020-2025 | Evoque |
| Magenta Medical INC | $3,300.00 | 2025 | |
| Medtronic Vascular, INC. | $1,577.39 | 2019 | |
| Abbott Laboratories | $1,564.80 | 2023-2025 | Amplatzer Amulet, Triclip |
| Boston Scientific Corporation | $292.57 | 2022 | |
| Csl Behring | $22.86 | 2020 | |
| Vapotherm INC | $12.49 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frederick Ling listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.